Company profile
Vericel Corp
NASDAQ:VCELBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| Anacaulase-BCDB | approved | — | 0 | — |
| AUTOLOGOUS CULTURED CHONDROCYTES | approved | — | 1 | approved |
Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.
Clinical trials (12)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03588975 | phase3 | recruiting | 2018-10-24 | 2030-02-01 | Vericel Corporation | A Study of MACI in Patients Aged 10 to 17 Years With Symptomatic Chondral or Osteochondral Defects of the Knee |
| NCT06915233 | phase3 | recruiting | 2026-05-28 | 2030-07-01 | Vericel Corporation | A Study of MACI in Patients Aged 17 to 65 Years With Symptomatic Chondral or Osteochondral Defects of the Ankle |
| NCT01483898 | phase3 | completed | 2012-02-01 | 2014-03-25 | Vericel Corporation | An Efficacy and Safety Study of Ixmyelocel-T in Patients With Critical Limb Ischemia (CLI) |
| NCT01670981 | phase2 | completed | 2013-02-20 | 2016-02-01 | Vericel Corporation | An Efficacy, Safety and Tolerability Study of Ixmyelocel-T Administered Via Transendocardial Catheter-based Injections to Subjects With Heart Failure Due to Ischemic Dilated Cardiomyopathy (IDCM) |
| NCT00424567 | phase1_2 | terminated | 2003-10-01 | — | Vericel Corporation | Feasibility Study of Aastrom Tissue Repair Cells to Treat Non-Union Fractures. |
FDA applications (3)
| Application | Type | Applicant | Products | |||
|---|---|---|---|---|---|---|
| BLA 103661 | BLA | Vericel Corporation | ||||
Loading… | ||||||
| BLA 125603 | BLA | Vericel Corporation | ||||
Loading… | ||||||
| BLA 761192 | BLA | Vericel Corporation | ||||
Loading… | ||||||